These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1243 related articles for article (PubMed ID: 31636208)

  • 1. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
    Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
    Wei SC; Levine JH; Cogdill AP; Zhao Y; Anang NAS; Andrews MC; Sharma P; Wang J; Wargo JA; Pe'er D; Allison JP
    Cell; 2017 Sep; 170(6):1120-1133.e17. PubMed ID: 28803728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
    Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
    Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
    Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
    Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8
    Taggart D; Andreou T; Scott KJ; Williams J; Rippaus N; Brownlie RJ; Ilett EJ; Salmond RJ; Melcher A; Lorger M
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1540-E1549. PubMed ID: 29386395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.
    Caudana P; Núñez NG; De La Rochere P; Pinto A; Denizeau J; Alonso R; Niborski LL; Lantz O; Sedlik C; Piaggio E
    Cancer Immunol Res; 2019 Mar; 7(3):443-457. PubMed ID: 30651291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
    Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
    Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8
    Wang K; Coutifaris P; Brocks D; Wang G; Azar T; Solis S; Nandi A; Anderson S; Han N; Manne S; Kiner E; Sachar C; Lucas M; George S; Yan PK; Kier MW; Laughlin AI; Kothari S; Giles J; Mathew D; Ghinnagow R; Alanio C; Flowers A; Xu W; Tenney DJ; Xu X; Amaravadi RK; Karakousis GC; Schuchter LM; Buggert M; Oldridge D; Minn AJ; Blank C; Weber JS; Mitchell TC; Farwell MD; Herati RS; Huang AC
    Cancer Cell; 2024 Sep; 42(9):1582-1597.e10. PubMed ID: 39214097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic T-Lymphocyte-Associated Antigen 4 (CTLA-4)- and Programmed Death 1 (PD-1)-Mediated Regulation of Monofunctional and Dual Functional CD4
    Rajamanickam A; Munisankar S; Dolla C; Nutman TB; Babu S
    Infect Immun; 2019 Dec; 87(12):. PubMed ID: 31570560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
    Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
    Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
    [No Abstract]   [Full Text] [Related]  

  • 16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
    Redmond WL; Linch SN; Kasiewicz MJ
    Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of PD-1 blockade in cervical cancer is related to a CD8
    Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD
    J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.